• Molecular NameFlutamide
  • SynonymFlutamide USP25; FTA
  • Weight276.214
  • Drugbank_IDDB00499
  • ACS_NO13311-84-7
  • Show 2D model
  • LogP (experiment)3.35
  • LogP (predicted, AB/LogP v2.0)3.37
  • pkaN/A
  • LogD (pH=7, predicted)3.37
  • Solubility (experiment)0.00945 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.88
  • LogSw (predicted, AB/LogsW2.0)0.05
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA77.93
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral nonsteroidal antiandrogen drug primarily used to treat prostate cancer.
  • Absorption_value100.0
  • Absorption (description)Rapidly and completely absorbed.
  • Caco_2N/A
  • Bioavailability90.0
  • Protein binding95.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFlutamide (F) is metabolized rapidly to a number of metabolites, which are mainly excreted in urine. One major metabolite, 2-hydroxyflutamide (HF), is biologically active (equal potency); formation is catalyzed primarily by CYP1A2.
  • Half life7.8 h
  • Excretion>90% via urine
  • Urinary Excretion<1
  • Clerance280 ml/min/kg
  • ToxicityThe most common side effect is gynecomastia
  • LD50 (rat)N/A
  • LD50 (mouse)N/A